Will We Be Able to "Cure" Metastatic Renal Cell Carcinoma Like We Cure Testicular Tumours?

European Urology

Volumn 54, Issue 4, 2008, Pages 712-714

  Kirkali, Ziya ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG INHIBITION; DRUG TOLERABILITY; EDITORIAL; GENE OVEREXPRESSION; GERM CELL TUMOR; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MEDICAL INFORMATION; MEDICAL SOCIETY; PALLIATIVE THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TESTIS TUMOR; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MALE; REMISSION INDUCTION; TESTICULAR NEOPLASMS;

EID: 50849111087     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.082     Document Type: Editorial

References (13)

1. Ravaud A., Wallerand H., Culine S., et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 54 (2008) 315-325
2. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
3. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 370 (2007) 2103-2111
4. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
5. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
6. Whorf R.C., Hainsworth J.D., Spigel D.R., et al. Phase II study of bevacizumab and everolimus in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 26 15S (2008) 252s
7. Motzer R.J., Escudier B., Oudard S., et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase III study. J Clin Oncol 26 15S (2008) 256s
8. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. Cancer 110 (2007) 2448-2457
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer V.I.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf.
10. Ljungberg B., Hanbury B.C., Kuczyk M.A., et al. Renal cell carcinoma guideline. Eur Urol 51 (2007) 1502-1510
11. Figlin R.A., Hutson T.E., and Tomczak P. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 15S (2008) 256s
12. Bukowski R.M., Stadler W.M., Figlin R.A., et al. Safety and efficacy of sorafenib in elderly pts >65 years: a subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. J Clin Oncol 26 15S (2008) 260s
13. Bhojani N., Jeldres C., Patard J.-J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal call carcinoma. Eur Urol 53 (2008) 917-930